Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 205

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 6
Chunk 205
---
 National Cancer Institute of the NIH
in Bethesda, MD.

Robert Den, MDhas
served as our Chief Medical Officer since 2019. Dr. Den specializes in radiation oncology and conducts innovative research across a broad
variety of malignancies. From 2011 to 2015 and from 2015 to the present, Dr. Den has served as an assistant professor and an associate
professor, respectively, at Jefferson University, where he has also served as a clinical practitioner since 2007. Dr. Den holds a B. S.
in Chemistry from Yale University and an M. D. from Harvard Medical School.

Amnon Gathas served
as our Chief Operations Officer since 2018, after having served as our VP of Marketing and Business Development and then VP of Operations
between 2016 and 2018. Mr. Gat also served as a director of Alpha Tau Medical Canada from 2019 until 2021. Mr. Gat leads our operations
in the United States and has over 20 years of experience in the medical device and healthcare industries. Prior to joining us, Mr. Gat
held managerial positions in public and private companies, such as Brainsway Ltd. (NASDAQ: BWAY) from 2011 until 2015, OSG Optimal Strategix
Group, Inc. from 2010 until 2011, and Truphatek International Ltd. from 2007 until 2009, and served as a senior paramedic in the Israeli
national emergency services. Mr. Gat holds a BA from The Open University of Israel and an MBA in International Management and Marketing
from the Interdisciplinary Center, Herzliya.

Ronen Segalhas served
as our Chief Technology Officer since 2019. Mr. Segal has served in a variety of senior managerial and technological development positions,
including at Brainsway Ltd (NASDAQ: BWAY), where he served as Chief Technology Officer, Deputy CEO and Head of Business Development from
2010 until 2018, and co-founder and Vice President at WiTech Communications Ltd. from 2004 until 2010. Mr. Segal completed studies in
1994 toward a BSc in Electro-Optical Engineering and Applied Physics at the Jerusalem College of Technology.

Peter Melnykhas served
as our Chief Commercial Officer since 2022, and previously served as a member of our board of directors from 2020 until 2022. From 2019
until 202